Journal
JOURNAL OF DIABETES
Volume 5, Issue 3, Pages 241-253Publisher
WILEY
DOI: 10.1111/1753-0407.12046
Keywords
antidiabetic drugs; dipeptidyl peptidase 4 inhibitors; glucagon-like peptide-1 receptor agonists; incretin analogs; type 2 diabetes therapy
Categories
Funding
- Novo Nordisk
- Amylin
- GSK
Ask authors/readers for more resources
The present short review summarizes and updates clinical experience with two classes of drugs introduced for the management of type 2 diabetes mellitus over the past 8 years: (i) the glucagon-like peptide-1 receptor agonists; and (ii) the dipeptidyl peptidase 4 inhibitors. Both classes of agents address the so called incretin defect in patients with T2DM.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
